This webinar is an AAOS benefit: Attend for free!
Description
This collaborative webinar, developed by the U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) and the American Academy of Orthopaedic Surgeons (AAOS), will explore the current evidence regarding the safety and effectiveness of Hip Resurfacing Arthroplasty (HRA) and Total Hip Arthroplasty (THA) devices. Experienced hip arthroplasty surgeons and key stakeholders will share clinical insights on the use of existing HRA and THA technologies in U.S. patients, as well as scientific and clinical advances that have renewed interest in next‑generation HRA devices as a potential alternative to THA for select populations. FDA/CDRH experts will outline regulatory considerations for introducing new orthopedic hip devices, including expectations for non‑clinical testing and clinical study data. Interactive panel discussions will focus on identifying the types of evidence that would most meaningfully advance understanding of the benefits and risks of HRA and THA devices.
Learning Objectives
After attending this webinar, participants will be able to:
1. Describe the current clinical performance, benefits, and risks of HRA and THA devices based on shared surgeon experience, published evidence, and real‑world use in U.S. patients.
2. Identify key scientific and technological developments driving interest in next‑generation HRA devices and how these innovations compare with established THA approaches for select patient groups.
3. Explain FDA/CDRH regulatory expectations for new hip arthroplasty devices, including required non‑clinical testing, clinical data considerations, and evidence needed to support a comprehensive assessment of device safety and effectiveness.
Webinar Faculty
Vincent Devlin, MD, Joshua Jacobs, MD, Edwin Su, MD, James Huddleston III, MD, Richard de Steiger, MBBS, PhD, Douglas Van Citters, PhD, James Nevelos, PhD, Ryan Trombetta, PhD, Bryan Springer, MD, Dave Jevsevar, MD
If you are unable to attend the live webinar, you may still register to be notified upon the availability of the recorded session. Access to the recording will be granted for a duration of 2 years.